The Medical Marijuana and Cannabidiol Research Expansion Act

Prior to 2022, the federal government allowed only a single entity—the National Center for Natural Products Research at the University of Mississippi—to develop research-grade medical marijuana. Section 101 amends the CSA by redesignating various paragraphs to allow the US attorney general to regist...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacy times 2023-10, Vol.89 (10)
Main Author: Carr, Abbey F
Format: Article
Language:English
Subjects:
Attorneys general
Cannabidiol
Controlled substances
Drug stores
Manufacturers
Medical marijuana
Product testing
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prior to 2022, the federal government allowed only a single entity—the National Center for Natural Products Research at the University of Mississippi—to develop research-grade medical marijuana. Section 101 amends the CSA by redesignating various paragraphs to allow the US attorney general to register a practitioner to conduct research with marijuana (including any derivative, preparation, extract, and compound) if the research application is approved and reviewed by a federal agency that funds scientific research, the US Secretary of Health and Human Services (HHS), or the Drug Enforcement Administration (DEA), and adheres to regulations of Schedule I substances research. Packaging requirements may include the use of tamper resistant and childproof material. [...]regulations are approved at the federal level, varying regulation among states can impose risk for consumers.3 The MMCREA was the beginning of a federal attempt to streamline the research process for medicinal marijuana and cannabidiol, ensure adequate supply for research purposes, and provide more attainable security requirements.
ISSN:0003-0627